Biogen has acquired TJ Biopharma’s exclusive rights to felzartamab in Greater China for $100 million upfront, up to $750 million in potential milestones, and region-specific royalties, consolidating global ownership of the CD38-directed antibody across all indications. The move folds the last major regional carve-out into Biogen’s portfolio following its 2024 purchase of Hi-Bio, and positions the company to lead development, manufacturing coordination, and commercialization in a market with some of the world’s largest patient pools for IgA nephropathy and primary membranous nephropathy. A biologics license application for multiple myeloma remains under review by China’s National Medical Products Administration, while global phase 3 programs continue in antibody-mediated rejection in kidney transplant, IgA nephropathy, and primary membranous nephropathy with China sites already active in two of the studies.
The strategic question is whether Biogen can convert an oncology-class mechanism into a durable immunology franchise at scale, beginning in China. Aggregating worldwide rights removes governance friction, harmonizes study operations and labeling strategy, and streamlines pricing and evidence plans—an increasingly essential alignment as payers demand coherent value narratives across indications. For a plasma cell–depleting therapy aimed at autoantibody-driven disease, the bar will not be set by response rates alone, but by demonstrable reductions in progression to end-stage kidney disease, steroid and rituximab sparing, and a safety-economic profile that can survive real-world immunosuppression scrutiny.
The timing matters. China’s nephrology burden is large and growing, and recent reforms have accelerated review timelines while intensifying budget discipline at NRDL negotiations. If multiple myeloma approval lands first, it could establish brand presence and supply reliability through TJ Biopharma’s Hangzhou facility before immunology labels arrive, but it may also anchor payer expectations for discounts in a CD38 class already shaped by entrenched competitors in oncology. For IgA nephropathy and membranous nephropathy, Biogen’s bet is that targeted depletion of CD38+ plasma cells will offer a clinically and economically superior route to durable proteinuria reduction and kidney function preservation versus established options and fast-following mechanisms.
Medical Affairs teams will need to define the adoption pathway across nephrology and transplant centers, focusing on infection risk management, immunoglobulin monitoring, vaccination strategies, and retreatment protocols in chronic care settings that differ materially from oncology infusion suites. Real-world data in Chinese populations—particularly on hospitalization, immunoglobulin replacement rates, and time to dialysis—will be central to NRDL negotiations and hospital budgeting. HCP education will also need to reconcile how a class familiar from multiple myeloma can be operationalized in autoimmune workflows, potentially alongside SGLT2 inhibitors, RAS blockade, and emerging disease-modifying agents.
Commercially, the landscape is tightening. In IgA nephropathy, payers will compare a high-cost biologic to steroidal approaches, endothelin receptor antagonists, and APRIL/BAFF-targeted agents moving through China, while in transplant AMR there is growing off-label experience with plasma cell–active drugs that may pressure dosing and duration assumptions. Competitors pursuing modular, mechanism-agnostic renal platforms are building bundled evidence packages that link biomarkers to hard outcomes, raising the bar for any single-asset strategy. Biogen’s control of global rights offers leverage to synchronize endpoints, health-economic models, and registries, yet it also concentrates risk in a single pipeline-in-a-product thesis.
The next signal to watch is whether Biogen sequences pricing and access around an oncology-first entry or withholds its commercial posture until renal readouts clarify the value story. If phase 3 data demonstrate sustained kidney protection with manageable immunosuppression costs, felzartamab could catalyze a broader shift toward plasma cell–directed therapy in autoimmune disease. If not, the class may remain bounded by oncology economics. The difference will hinge on how quickly China-specific outcomes and cost offsets are generated and translated into payer contracts.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
